Clinical trials: Radiotherapy Side Effect
Cisplatin Ototoxicity, Hearing Loss
Randomized Trial Comparison of Ototoxicity Monitoring Programs
This study involves research. Some chemotherapeutic drugs that can permanently reduce hearing are termed "ototoxic". One such drug is the chemotherapy called cisplatin.
- Trial name
- COMP-VA (NCT02099786)
- Testing
- COMP-VA, Standard of care
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Cardiac Toxicity, Chemotherapeutic Agent Toxicity
Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma
- Trial name
- NCT00577798
- Testing
- contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Cardiotoxicity
Staccato Prochlorperazine Thorough QT/QTc
To assess the safety of Staccato Prochlorperazine on cardiac repolarization (QTc interval duration) at 2 dose levels compared to placebo in healthy volunteers.
- Trial name
- NCT00543062
- Testing
- Inhaled prochlorperazine 5 mg, Inhaled prochlorperazine 10 mg, Oral moxifloxacin
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Alexza Pharmaceuticals, Inc.